Indications up for PET
Wednesday, 16 July, 2008
The Australian Government has expanded approved indications for Medicare reimbursement for PET imaging.
The inclusion of ovarian cancer, colorectal cancer and recurrent melanoma brings to a total of six the number of PET indications which are approved for reimbursement through Medicare.
One company poised to take advantage of this decision is Cyclopharm [ASX: CYC], which has already commenced development of two PET radiopharmacy sites.
The first is to be built at the Macquarie University Private Hospital, and should be completed in the first half of next year.
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
Existing medicines could help treat deadly childhood dementia
Australian researchers have identified several existing TGA‑approved medicines that could help...
Statins reduce heart attack and stroke risk in older people
It has previously been unclear whether statins were effective in reducing heart attack and stroke...
